A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
Richard A Glennon, M Titeler, R A Lyon
Pharmacology, Biochemistry, and Behavior July 1988 DOI: 10.1016/0091-3057(88)90071-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical pharmacological study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | 4-Bromo-2 5-dimethoxyphenethylamine (alpha-desMe DOB) |
| Key points | Alpha-desMe DOB binds with high affinity to 5-HT2 serotonin receptors (Ki = 1 nM) but, unlike DOB, also binds to 5-HT1A, 5-HT1B, and 5-HT1C receptors, making it less selective. In drug discrimination studies, it produced stimulus generalization in rats trained to discriminate DOM or R(-)DOB from saline, though with extensive behavioral disruption. The authors tentatively conclude it is a psychoactive agent with at least some hallucinogenic or DOB-like properties. |
Abstract
4-Bromo-2,5-dimethoxyphenethylamine (alpha-desMe DOB) is a psychoactive agent that may possess significant abuse potential. Because of its structural similarity to the established hallucinogen 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB), and because almost no pharmacological data are available on this agent, we undertook this preliminary investigation. alpha-DesMe DOB (Ki = 1 nM), like DOB itself (Ki = 0.79 nM), displays a high affinity for [3H]DOB-labeled central 5-HT2 serotonin receptors. However, unlike DOB, the alpha-desmethyl derivative also binds with significant affinity to 5-HT1A, 5-HT1B, and 5-HT1C serotonin receptors and, as such, is less selective than DOB. In drug discrimination studies using rats trained to discriminate either DOM (i.e., the 4-methyl analog of DOB) or R(-)DOB from saline, stimulus generalization occurred in both groups of animals. However, stimulus generalization was associated with extensive disruption of behavior, alpha-DesMe DOB may produce stimulus effects similar, but not identical, to those of DOM and R(-)DOB; in addition, this agent may be capable of producing other, as yet undefined, central effects at comparable doses. These other effects may be reflective of the lack of selectivity of alpha-desMe DOB for 5-HT2 serotonin receptors. Because other hallucinogenic agents display high affinity for 5-HT2 serotonin receptors and result in stimulus generalization in DOM- and/or DOB-trained animals, it is tentatively concluded that alpha-desMe DOB is a psychoactive agent with at least some hallucinogenic or DOB-like properties.
Citations in the library
Cited by 21
- Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology May 1, 2020
- Metabolism of designer drugs of abuse: an updated review. Current Drug Metabolism June 1, 2010
- Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology January 5, 2005
- Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochemical Pharmacology January 15, 2007
- 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. Journal of Analytical Toxicology September 1, 1998
and 16 more in the library
Cites 4
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Molecular Pharmacology February 1, 1987
- Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacology, Biochemistry, and Behavior March 1988
- Site-selective serotonin agonists as discriminative stimuli. Psychopharmacology series 1988